TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$BIORCE · Las farmacéuticas pagan decenas de millones por esta IA | Biorce
now playing · $BIORCE
$BIORCEbullish· high· pospedro coelho
Biorce reaches $10M ARR in 9 months, targets $10B+ revenue clinical trial OS
Biorce's AI operating system for clinical trials cuts protocol creation from 18 months to 10 minutes with 95% accuracy, reducing pharma R&D costs by 50-70%. The company achieved ~…
$GOOGL···bullish· mediumpedro coelho
DeepMind partnership enables Biorce's reasoning model training approach
Biorce has a strategic partnership with Google/DeepMind where the Head of Research shared pre-public reasoning training techniques (Chain of Thought) that Biorce adopted to train…
$ANTHROPICneutral· mediumpedro coelho
Biorce uses Anthropic as best-in-class for math/statistics tasks in model orchestration
Biorce's model orchestrator routes tasks to the best model: proprietary models for domain-specific clinical reasoning, Anthropic for mathematics/statistics/SQL where frontier mode…
$FORMATION-BIOneutral· mediumpedro coelho
Formation Bio raises billions to become AI-native pharma, not infrastructure
Formation Bio took the opposite approach to Biorce: raising billions to develop drugs themselves as an AI-native pharmaceutical company rather than selling infrastructure to pharm…
$MAZEbullish· mediumpedro coelho
Maze Impact first institutional investor in Biorce, backed pre-seed at 3.5M EUR
Maze (Portuguese impact fund) was the first investor to understand Biorce's hybrid tech-bio positioning, committing 1M EUR in pre-seed when health tech and pure tech funds both pa…
$NORSKENbullish· highpedro coelho
Norsken converts CL to equity at 9x ARR multiple after witnessing pharma demand
Norsken invested via a convertible note with revenue-based conversion (9-10x ARR) after observing Biorce's team execution and a major pharma visit where 7 leadership members reque…
$DST-GLOBALbullish· highpedro coelho
DST Global leads Biorce Series A after 3-day founder shadowing, no reference calls
DST Global (Yuri Milner) invested in Biorce's $52.5M Series A after intensive due diligence including 3-day founder shadowing and a demo to ex-GSK/Genentech/Rush executives. They…
$BAYRY···neutral· highpedro coelho
Bayer offers ~$2B for Biorce, turned down to remain neutral infrastructure
A major pharma (likely Bayer per context) offered approximately $2B cash for Biorce. The founder rejected it because selling to one pharma would compromise the neutral infrastruct…